Smith Group Asset Management’s Galectin Therapeutics GALT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-57,970
| Closed | -$85K | – | 469 |
|
|
2016
Q2 | $85K | Buy |
57,970
+23,700
| +69% | +$34.8K | ﹤0.01% | 319 |
|
|
2016
Q1 | $49K | Buy |
34,270
+8,180
| +31% | +$11.7K | ﹤0.01% | 319 |
|
|
2015
Q4 | $43K | Buy |
26,090
+4,990
| +24% | +$8.22K | ﹤0.01% | 343 |
|
|
2015
Q3 | $49K | Buy |
21,100
+2,944
| +16% | +$6.84K | ﹤0.01% | 285 |
|
|
2015
Q2 | $50K | Buy |
18,156
+1,522
| +9% | +$4.19K | ﹤0.01% | 279 |
|
|
2015
Q1 | $56K | Buy |
+16,634
| New | +$56K | ﹤0.01% | 327 |
|